Hims in Tennessee

Is Hims legit?

No verdict has been issued yet. This is a neutral factual record. Hims (hims.com) is the men's brand of Hims & Hers Health, Inc. (NYSE: HIMS), a publicly traded telehealth company headquartered in San Francisco; this record is scoped to its GLP-1 weight-loss program only. As of mid-2026 the weight-loss lineup is brand-name only: Wegovy pill (from $149/mo) and pen (from $199/mo), Ozempic pill (from $149/mo) and injection (from $199/mo), Zepbound vial and KwikPen (from $299/mo), Lilly's Foundayo pill (from $149/mo), and Mounjaro/Zepbound pens at $1,899/mo - all requiring a separately billed Weight Loss Membership ($39 first month, auto-renewing at $149/mo) that does not include or guarantee a prescription. Its own weight-loss page states the offering is 'not available in all 50 states,' so all-50 coverage is recorded as not confirmed even though its affiliated medical groups have providers in all 50 states. The compounded-semaglutide era that preceded this lineup generated the densest weight-loss-program controversy record of any clinic reviewed on this site, all of it precisely dateable: a Novo Nordisk partnership announced April 29, 2025 and publicly terminated June 23, 2025 over alleged 'illegal mass compounding' and 'deceptive marketing' (shares fell roughly a third); securities class actions filed June 25, 2025 (consolidated in N.D. Cal.) plus three derivative suits; FDA misbranding warning letters to both Hims and Hers dated September 9, 2025; a December 2025 FDA warning letter to its own 503B facility MedisourceRx over unreported patient hospitalization; a February 5, 2026 launch of a $49/mo compounded Wegovy-copy pill that was withdrawn two days later (February 7) after the FDA named the company in a February 6 enforcement statement and HHS referred it to the DOJ; a Novo patent suit filed February 9, 2026; an SEC enforcement investigation opened February 2026; and a consumer false-advertising class action filed February 20, 2026. On March 9, 2026 Hims and Novo settled - Novo dismissed its suit without prejudice and Hims agreed to stop advertising compounded GLP-1s and transition patients to branded drugs, retaining compounded access only for documented clinical necessity. The DOJ referral, SEC investigation, securities and consumer suits remained unresolved as of the access date.

Is Hims's pharmacy licensed in Tennessee?

Strive Pharmacy, RedRock Pharmacy verified licensed in Tennessee by the state board.

Does Hims ship to Tennessee?

Ship-to coverage for Hims is still in review — unknown, not excluded. Confirm Tennessee availability at the clinic's own checkout.

How much does Hims cost?

Compounded semaglutide from $199/mo (12-mo prepay) — observed market pricing, snapshot 2026-07-20.